Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning

Alessandro Aiuti, Shimon Slavin, Memet Aker, Francesca Ficara, Sara Deola, Alessandra Mortellaro, Shoshana Morecki, Grazia Andolfi, Antonella Tabucchi, Filippo Carlucci, Enrico Marinello, Federica Cattaneo, Sergio Vai, Paolo Servida, Roberto Miniero, Maria Grazia Roncarolo, Claudio Bordignon

Research output: Contribution to journalArticle

886 Citations (Scopus)

Abstract

Hematopoietic stem cell (HSC) gene therapy for adenosine deaminase (ADA)deficient severe combined immunodeficiency (SCID) has shown limited clinical efficacy because of the small proportion of engrafted genetically corrected HSCs. We describe an improved protocol for gene transfer into HSCs associated with nonmyeloablative conditioning. This protocol was used in two patients for whom enzyme replacement therapy was not available, which allowed the effect of gene therapy alone to be evaluated. Sustained engraftment of engineered HSCs with differentiation into multiple lineages resulted in increased lymphocyte counts, improved immune functions (including antigen-specific responses), and lower toxic metabolites. Both patients are currently at home and clinically well, with normal growth and development. These results indicate the safety and efficacy of HSC gene therapy combined with nonmyeloablative conditioning for the treatment of SCID.

Original languageEnglish
Pages (from-to)2410-2413
Number of pages4
JournalScience
Volume296
Issue number5577
DOIs
Publication statusPublished - 28 Jun 2002
Externally publishedYes

Fingerprint

Severe Combined Immunodeficiency
Adenosine Deaminase
Cell- and Tissue-Based Therapy
Genetic Therapy
Stem Cells
Hematopoietic Stem Cells
Enzyme Replacement Therapy
Poisons
Lymphocyte Count
Growth and Development
Safety
Antigens
Genes
Therapeutics

ASJC Scopus subject areas

  • General

Cite this

Aiuti, A., Slavin, S., Aker, M., Ficara, F., Deola, S., Mortellaro, A., ... Bordignon, C. (2002). Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning. Science, 296(5577), 2410-2413. https://doi.org/10.1126/science.1070104

Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning. / Aiuti, Alessandro; Slavin, Shimon; Aker, Memet; Ficara, Francesca; Deola, Sara; Mortellaro, Alessandra; Morecki, Shoshana; Andolfi, Grazia; Tabucchi, Antonella; Carlucci, Filippo; Marinello, Enrico; Cattaneo, Federica; Vai, Sergio; Servida, Paolo; Miniero, Roberto; Roncarolo, Maria Grazia; Bordignon, Claudio.

In: Science, Vol. 296, No. 5577, 28.06.2002, p. 2410-2413.

Research output: Contribution to journalArticle

Aiuti, A, Slavin, S, Aker, M, Ficara, F, Deola, S, Mortellaro, A, Morecki, S, Andolfi, G, Tabucchi, A, Carlucci, F, Marinello, E, Cattaneo, F, Vai, S, Servida, P, Miniero, R, Roncarolo, MG & Bordignon, C 2002, 'Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning', Science, vol. 296, no. 5577, pp. 2410-2413. https://doi.org/10.1126/science.1070104
Aiuti, Alessandro ; Slavin, Shimon ; Aker, Memet ; Ficara, Francesca ; Deola, Sara ; Mortellaro, Alessandra ; Morecki, Shoshana ; Andolfi, Grazia ; Tabucchi, Antonella ; Carlucci, Filippo ; Marinello, Enrico ; Cattaneo, Federica ; Vai, Sergio ; Servida, Paolo ; Miniero, Roberto ; Roncarolo, Maria Grazia ; Bordignon, Claudio. / Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning. In: Science. 2002 ; Vol. 296, No. 5577. pp. 2410-2413.
@article{a159f525dc444f65aed3127c9a822298,
title = "Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning",
abstract = "Hematopoietic stem cell (HSC) gene therapy for adenosine deaminase (ADA)deficient severe combined immunodeficiency (SCID) has shown limited clinical efficacy because of the small proportion of engrafted genetically corrected HSCs. We describe an improved protocol for gene transfer into HSCs associated with nonmyeloablative conditioning. This protocol was used in two patients for whom enzyme replacement therapy was not available, which allowed the effect of gene therapy alone to be evaluated. Sustained engraftment of engineered HSCs with differentiation into multiple lineages resulted in increased lymphocyte counts, improved immune functions (including antigen-specific responses), and lower toxic metabolites. Both patients are currently at home and clinically well, with normal growth and development. These results indicate the safety and efficacy of HSC gene therapy combined with nonmyeloablative conditioning for the treatment of SCID.",
author = "Alessandro Aiuti and Shimon Slavin and Memet Aker and Francesca Ficara and Sara Deola and Alessandra Mortellaro and Shoshana Morecki and Grazia Andolfi and Antonella Tabucchi and Filippo Carlucci and Enrico Marinello and Federica Cattaneo and Sergio Vai and Paolo Servida and Roberto Miniero and Roncarolo, {Maria Grazia} and Claudio Bordignon",
year = "2002",
month = "6",
day = "28",
doi = "10.1126/science.1070104",
language = "English",
volume = "296",
pages = "2410--2413",
journal = "Science",
issn = "0036-8075",
publisher = "American Association for the Advancement of Science",
number = "5577",

}

TY - JOUR

T1 - Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning

AU - Aiuti, Alessandro

AU - Slavin, Shimon

AU - Aker, Memet

AU - Ficara, Francesca

AU - Deola, Sara

AU - Mortellaro, Alessandra

AU - Morecki, Shoshana

AU - Andolfi, Grazia

AU - Tabucchi, Antonella

AU - Carlucci, Filippo

AU - Marinello, Enrico

AU - Cattaneo, Federica

AU - Vai, Sergio

AU - Servida, Paolo

AU - Miniero, Roberto

AU - Roncarolo, Maria Grazia

AU - Bordignon, Claudio

PY - 2002/6/28

Y1 - 2002/6/28

N2 - Hematopoietic stem cell (HSC) gene therapy for adenosine deaminase (ADA)deficient severe combined immunodeficiency (SCID) has shown limited clinical efficacy because of the small proportion of engrafted genetically corrected HSCs. We describe an improved protocol for gene transfer into HSCs associated with nonmyeloablative conditioning. This protocol was used in two patients for whom enzyme replacement therapy was not available, which allowed the effect of gene therapy alone to be evaluated. Sustained engraftment of engineered HSCs with differentiation into multiple lineages resulted in increased lymphocyte counts, improved immune functions (including antigen-specific responses), and lower toxic metabolites. Both patients are currently at home and clinically well, with normal growth and development. These results indicate the safety and efficacy of HSC gene therapy combined with nonmyeloablative conditioning for the treatment of SCID.

AB - Hematopoietic stem cell (HSC) gene therapy for adenosine deaminase (ADA)deficient severe combined immunodeficiency (SCID) has shown limited clinical efficacy because of the small proportion of engrafted genetically corrected HSCs. We describe an improved protocol for gene transfer into HSCs associated with nonmyeloablative conditioning. This protocol was used in two patients for whom enzyme replacement therapy was not available, which allowed the effect of gene therapy alone to be evaluated. Sustained engraftment of engineered HSCs with differentiation into multiple lineages resulted in increased lymphocyte counts, improved immune functions (including antigen-specific responses), and lower toxic metabolites. Both patients are currently at home and clinically well, with normal growth and development. These results indicate the safety and efficacy of HSC gene therapy combined with nonmyeloablative conditioning for the treatment of SCID.

UR - http://www.scopus.com/inward/record.url?scp=0037189401&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037189401&partnerID=8YFLogxK

U2 - 10.1126/science.1070104

DO - 10.1126/science.1070104

M3 - Article

VL - 296

SP - 2410

EP - 2413

JO - Science

JF - Science

SN - 0036-8075

IS - 5577

ER -